• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

37.62 +0.21 (+0.56%)
Delayed Quote Updated: 4:00 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Xenon to Report Q3 2026 Financial Results on November 9, 2026
November 02, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 30, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
October 29, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals (NASDAQ:XENE) Presents High-Quality Technical Breakout Setup ↗
August 13, 2026
Via Chartmill
Xenon Pharmaceuticals (NASDAQ:XENE) Reports Mixed Q1 Results as Azetukalner Nears FDA Submission ↗
May 07, 2026
Via Chartmill
News headline image
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review ↗
September 27, 2026
Xenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program... 
Via MarketBeat
News headline image
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
September 23, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 21, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Triple Witching Whipsaws Wall Street While Crypto Stocks Steal the Show ↗
September 21, 2026
Via Chartmill
Top stock movements in today's session. ↗
September 18, 2026
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
September 18, 2026
Via Chartmill
Friday's session: gap up and gap down stocks ↗
September 18, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
September 18, 2026
Via Chartmill
These stocks are moving in today's after hours session ↗
September 17, 2026
Via Chartmill
News headline image
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
September 17, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present at Wells Fargo Healthcare Conference
September 03, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 28, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
August 26, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Azetukalner advances toward FDA submission as pain pipeline matures. 
Via The Motley Fool
Topics Earnings
News headline image
Xenon Pharmaceuticals Q2 Earnings Call Highlights ↗
August 07, 2026
10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in... 
Via MarketBeat
Topics Earnings
News headline image
Xenon Reports Q2 2026 Financial Results and Provides Business Update
August 06, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Report Q2 2026 Financial Results on August 6, 2026
July 30, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
May 18, 2026
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
Via The Motley Fool
News headline image
Xenon Pharmaceuticals Q1 Earnings Call Highlights ↗
May 09, 2026
Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational... 
Via MarketBeat
Topics Earnings
News headline image
Xenon (XENE) Q1 2026 Earnings Transcript ↗
May 07, 2026
Xenon (XENE) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Xenon Reports Q1 2026 Financial Results and Provides Business Update
May 07, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap